NCT03363776View on ClinicalTrials.gov

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

November 22, 2019

Study Completion Date

November 22, 2019

Conditions
Cancer
Interventions
BIOLOGICAL

BMS-986277

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (3)

57104

Sanford Research, Sioux Falls

K1H 8L6

Local Institution, Ottawa

M5G 1Z5

Princess Margaret Cancer Centre, Toronto

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY